---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-015259"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:55:12.767574+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rallybio Q2 net loss $17.6M; Phase 1b RLYB212 shows platelet elimination; CFO to retire

## Summary
- Net loss $17.6M ($0.57/share) vs $11.1M ($0.49) in Q2 2021 on higher R&D and G&A expenses.
- Cash, equivalents and securities $147.4M as of June 30, 2022; runway into Q1 2024.
- Phase 1b RLYB212 shows rapid elimination of HPA-1a positive platelets; protocol amended for broader dose range.
- Phase 1 RLYB116 on track; initial single-dose data for 30 mg expected Q4 2022.
- CFO Jeffrey Fryer to retire; external search for successor begun.

## SEC filing metadata
- accession: 0000950170-22-015259
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000095017022015259/0000950170-22-015259-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000095017022015259/rlyb-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-015259
- JSON: https://secwatch.observer/filing/0000950170-22-015259.json
- Plain text: https://secwatch.observer/filing/0000950170-22-015259.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.